DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

This study is testing a new CAR-T cell therapy (a type of personalized immune cell treatment) called LB2102, which is designed to find and attack cancer cells that carry a specific marker called DLL3. It is intended for patients with extensive-stage small cell lung cancer or related lung cancers that have come back after prior treatment. **You may be eligible if...** - You are at least 18 years old - You have confirmed extensive-stage small cell lung cancer (SCLC), large cell neuroendocrine carcinoma, or related lung cancers - Your cancer has progressed after at least one standard treatment - You are in good health overall (ECOG 0–1) with a life expectancy of at least 4 months - Your organ function is adequate **You may NOT be eligible if...** - You have previously received CAR-T or gene therapy - You have previously been treated with DLL3-targeted therapies - You have symptomatic brain metastases or leptomeningeal spread - You have active autoimmune disease requiring immune-suppressing treatment - You have significant heart disease or uncontrolled infection - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.